前列地尔注射液对糖尿病肾病患者血浆ET、NO、FN的影响

Effects of alprostadil injection on plasma ET,NO and FN in patients with diabetic nephropathy

目的观察前列地尔注射液对糖尿病肾病(DN)患者血浆内皮素(ET)、一氧化氮(NO)、纤维蛋白原(FN)的影响。方法测定28例无肾病糖尿病患者、50例临床糖尿病肾病患者血浆ET、NO和FN水平,探讨血浆ET、NO和FN水平变化在糖尿病肾病发病中的可能作用。将50例糖尿病肾病患者随机分为两组,常规治疗组(对照组)和前列地尔治疗组(治疗组),测定两组治疗前后血浆ET、NO及FN水平、尿白蛋白排泄率(UAER)的变化。结果糖尿病肾病患者较无肾病糖尿病患者血浆ET、FN水平明显升高(P<0.01),血浆NO水平明显降低(P<0.01)。与对照组比较应用前列地尔治疗可使糖尿病肾病患者血浆ET、FN水平明显降低(均P<0.01),血浆NO水平明显升高(P<0.01),UAER明显降低(P<0.01)。结论血浆ET、FN水平升高,NO水平降低在糖尿病肾病的发病中发挥重要作用。前列地尔治疗可纠正糖尿病肾病患者血浆ET、NO和FN平衡失调,减少UAER,促进病情恢复。

Objective To observe the effects of alprostadil injection on diabetic nephropathy（DN） in patients with plasma endothelin（ET）,nitric oxide（NO） and fibrinogen（FN）.Methods Serum ET,NO and FN of 28 patients with diabetes without nephropathy and 50 patients with diabetic nephropathy were measured.The 50 patients with diabetic nephropathy were randomly divided into two groups,including conventional treatment group and alprostadil-treated group.Results The serum ET and FN of patients with diabetic nephropathy were significantly elevated（P0.01） compared with diabetic patients without nephropathy,but the serum NO of patients with diabetic nephropathy was were significantly lower than that without diabetic nephropathy（P0.01）.Alprostadil could decrease serum ET and FN and increase serum NO（P0.01）.Conclusion Serum ET,FN and NO levels play an important role on incidence of diabetic nephropathy.Alprostadil can plasma of patients with diabetic nephropathy rectify ET,NO and FN imbalance and reduce UAER.